www.lyciatx.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $406.62MM
Lycia Therapeutics is a biotechnology company and the developer of a treatment technology, Lysosomal Targeting Chimera (LYTAC), that aims to degrade extracellular proteins with the goal of treating conditions including cancer, inflammation, and autoimmune disorders. The company has a mission to uncover use cases for the LYTAC platform using extracellular protein degradation designed to target soluble and membrane-bound proteins. Lycia Therapeutics was founded in 2019 by Dr. Carolyn Bertozzi and is headquartered in San Francisco, CA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
05/13/2024 | Series C | $106.6MM | $xx.xx | $313.67MM | Alexandria Venture Investments, Blue Owl Healthcare Opportunities, Eli Lilly & Company, Franklin Templeton, Invus, Janus Henderson Investors, Marshall Wace, Redmile Group, Rtw Investments, Venrock Healthcare Capital Partners | |
Price per Share
$xx.xx
Shares Outstanding
52,211,394
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
3
Key Investors
Alexandria Venture Investments, Blue Owl Healthcare Opportunities, Eli Lilly & Company, Franklin Templeton, Invus, Janus Henderson Investors, Marshall Wace, Redmile Group, Rtw Investments, Venrock Healthcare Capital Partners
|
||||||
09/09/2021 | Series B | $71.32MM | $xx.xx | $195.08MM | Alexandria Venture Investments, Cowen Healthcare Investments, Eli Lilly & Company, Invus, Redmile Group, Rtw Investments, Versant Ventures | |
Price per Share
$xx.xx
Shares Outstanding
39,597,569
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
3
Key Investors
Alexandria Venture Investments, Cowen Healthcare Investments, Eli Lilly & Company, Invus, Redmile Group, Rtw Investments, Versant Ventures
|
||||||
06/09/2020 | Series A | $25.39MM | $xx.xx | $63.48MM | Versant Ventures | |
Price per Share
$xx.xx
Shares Outstanding
25,390,410
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
3
Key Investors
Versant Ventures
|